Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo. The data showed improved lean body mass and full adherence, addressing the two main drawbacks to GLP-1 therapies, while maintaining optimum weight loss at a reduced dosage, the analyst tells investors in a research note. This sets up well for a randomized trial anticipated later this year, which could potentially set up Allurion’s gastric balloon in combination with GLP-1’s as the new standard of care for patients seeking metabolically healthy weight loss, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion announces initial results from Allurion Program-GLP-1 combo
- Allurion Technologies price target lowered to $16 on split-adjusted basis
- Allurion Technologies announces issuance of new patents on weight loss device
- Allurion to sell 900,000 shares at $5.23 in registered direct offering
- Allurion Technologies to initiate Allurion Balloon with GLP-1 agonists study